Inozyme Pharma, Inc. (INZY)
NASDAQ: INZY · IEX Real-Time Price · USD
7.69
+0.30 (4.06%)
Mar 28, 2024, 2:55 PM EDT - Market open
Inozyme Pharma Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Inozyme Pharma stock have an average target of 18, with a low estimate of 15 and a high estimate of 23. The average target predicts an increase of 134.07% from the current stock price of 7.69.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Inozyme Pharma stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $16 | Strong Buy | Maintains | $16 | +108.06% | Mar 13, 2024 |
Needham | Needham | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +199.09% | Mar 12, 2024 |
Wedbush | Wedbush | Buy Reiterates $15 | Buy | Reiterates | $15 | +95.06% | Jan 30, 2024 |
Needham | Needham | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +199.09% | Nov 8, 2023 |
Needham | Needham | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +199.09% | Sep 27, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.37
from -1.37
EPS Next Year
-1.51
from -1.37
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | n/a | n/a | 39.1M | 238.2M | 560.0M |
Avg | n/a | n/a | 13.4M | 118.9M | 315.1M |
Low | n/a | n/a | 2.7M | 31.9M | 160.6M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | 1,681.4% | 371.1% |
Avg | - | - | - | 788.9% | 165.0% |
Low | - | - | - | 138.2% | 35.1% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -1.16 | -1.31 | -1.24 | 0.43 | 0.71 |
Avg | -1.37 | -1.51 | -1.30 | -0.14 | 0.69 |
Low | -1.62 | -1.81 | -1.33 | -0.67 | 0.67 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.